RANK signaling increases after anti-HER2 therapy contributing to the emergence of resistance in HER2-positive breast cancer.
Sanz-Moreno A, Palomeras S, Pedersen K, Morancho B, Pascual T, Galván P, Benítez S, Gomez-Miragaya J, Ciscar M, Jimenez M, Pernas S, Petit A, Soler-Monsó MT, Viñas G, Alsaleem M, Rakha EA, Green AR, Santamaria PG, Mulder C, Lemeer S, Arribas J, Prat A, Puig T, Gonzalez-Suarez E.
Sanz-Moreno A, et al. Among authors: pedersen k.
Breast Cancer Res. 2021 Mar 30;23(1):42. doi: 10.1186/s13058-021-01390-2.
Breast Cancer Res. 2021.
PMID: 33785053
Free PMC article.